Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma
ASCO Calls On NCI To Double Funding For Cooperative Group Clinical Trials
Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase
Bosutinib Vs. Imatinib Study Didn’t Meet Primary Endpoint
Autologous BMT Equivalent To Allogeneic For Myeloma
Non-Adherence To Protocol Explains Outcome Differences In Hispanic Children With ALL
Afinitor Delayed Progression Compared To Tamoxifen Alone In Randomized Phase II Study
AZURE Trial: Zoledronic Acid Didn’t Improve DFS In Stage II/III
Survival For ALL Increased To 94 Percent In Recent Years
TTF Increased Survival Compared To Chemotherapy
Randomized Trial Finds Sunscreen Use Cuts Risk Of Developing Melanoma
Clinical Trials Approved By NCI CTEP Last Month
Trending Stories
- On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors - Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
- After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored
